| dc.description.abstract | Introduction: Pancreatic cancer is the seventh leading cause of death globally in developing countries. Through the process, elevated serum CA 19-9 levels have become a diagnostic tumour marker frequently used to detect pancreatic cancer. Studies have shown that adjusting CA19-9 levels to serum bilirubin levels can improve accuracy in differentiating between benign and malignant hepatopancreaticobilier disease.
Objectives: We aimed to seek the correlation of bilirubin values with CA 19-9 levels in pancreatic cancer patients at H. Adam Malik General Hospital, Medan.
Methods: This is a descriptive-analytic study with a cross-sectional design with data collection carried out from July 2022 to November 2022, followed by processing and analysis of the data that has been collected. While the research sample was taken using the consecutive sampling method, determined with specific considerations, namely inclusion and exclusion criteria.
Results: The subject of this study averaged 62.59 + 4.28 years, the majority were male, as many as 159 people (78.3%), and the rest were female, as many as 44 people (21, 7%). Based on the staging, most research subjects were at stage III, as many as 78 people (38.4%), followed by subjects with stage II, as many as 50 people (24.6%); the rest were at stage IV, as many as 43 people (21.3%) and stage I as many as 32 people (15.7%). All study subjects found total bilirubin levels with an average value of 10.55 mg/dl with an SD of 2.75 mg/dl and CA19-9 levels with an average value of 145.28 U/ml an SD of 44.28. Then statistical analysis was carried out using the Spearman test and found a p-value <0.001 and a correlation coefficient of 0.971.
Conclusion: We found a significant relationship and strong correlation between CA 19-9 and total bilirubin in pancreatic cancer patients. | en_US |
